Clinical Trial

A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Phase I/II Dose-Finding Study to Evaluate Striatal Administration of AB-1001 (previously BV-101) in Adults with Early Manifest Huntington's Disease
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-09-13; most recent amendment 2026-05-12.
Status change: Recruiting → Active, Not Recruiting 2023-07-06
Status change: Not Yet Recruiting → Recruiting 2022-10-17
Trial Details
NCT Number NCT05541627
Lead Sponsor AskBio France, SAS, a subsidiary of AskBio Inc.
Conditions Huntington Disease
Enrollment 5 participants
Start Date 2022-10-12
Primary Completion 2024-04-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-14